Medication Prescribing

Resource Center

News
Research Summaries
Resources
FDA Alerts Pearls of Wisdom From the Journal
Insights
Commentary Podcasts Q&As Videos
Interactive
Polls Quizzes

Research Summaries

FDA ALERT
fda
FDA ALERT
FDA Approves Interchangeable Biosimilar for Psoriatic Arthritis, Other Inflammatory Conditions
11/08/2015
Anthony Calabro, MA
The FDA approved ustekinumab-auub as an interchangeable biosimilar with ustekinumab for multiple inflammatory diseases.
11/08/2015
FDA ALERT
FDA ALERT
FDA Approves Interchangeable Biosimilar for Psoriatic Arthritis, Other Inflammatory Conditions
11/08/2015
Anthony Calabro, MA
The FDA approved ustekinumab-auub as an interchangeable biosimilar with ustekinumab for multiple inflammatory diseases.
11/08/2015
Research Summary
GLP1-RA
Research Summary
GLP-1 Receptor Agonists and Postoperative Outcomes After Spinal Fusion
09/02/2015
Miranda Manier, BA
Perioperative GLP-1 receptor agonist use was associated with lower infection, readmission, and revision rates—and better mobility metrics—after spinal fusion in diabetic patients, with similar benefits in...
09/02/2015
Research Summary
epidural
Research Summary
Incidence and Risk Factors for Complications After Cervical Epidural Steroid Injections
09/02/2015
Miranda Manier, BA
Complications after cervical epidural steroid injections were rare but increased over time, with neurologic events most frequent and higher risk linked to the transforaminal approach and key patient...
09/02/2015
Research Summary
Person with migraine sitting at desk
Research Summary
Long-Term Safety and Tolerability of Rimegepant for Patients With Migraine
01/09/2015
Miranda Manier, BA
A recent study found that rimegepant, an orally administered calcitonin gene-related peptide receptor antagonist, is safe and well-tolerated for up to 52 weeks in individuals with migraine, with no signs of...
01/09/2015
Treatment
Treatment
Steroid-Sparing Agents and Patients With LV-GCA
05/05/2011
Patients with large-vessel giant cell arteritis may see disease improvement when treated early with steroid-sparing agents, recent research reveals.
05/05/2011
Treatment
Treatment
Study Reveals Principal Component Is Effective in Patient Profiling in RA
05/05/2011
During a patient-profiling, data-driven study, researchers reveal 5 phenotypes associated with patients with rheumatoid arthritis.
05/05/2011
Treatment
Treatment
Tocilizumab Proves Stabilizing in SSc Study
04/07/2011
Patients with early systemic sclerosis-associated lung disease experienced stabilized forced vital capacity with tocilizumab, researchers report.
04/07/2011
Treatment
Treatment
Researchers Investigate the Importance of Fatigue in SSc
04/07/2011
Researchers find helpful clinical interventions associated with managing fatigue in patients with systemic sclerosis.
04/07/2011
Treatment
Treatment
Research Tests Duration of Effect of Tocilizumab Among Patients With GCA
03/25/2011
Patients with giant cell arteritis see long-term effects after 1 year of treatment with tocilizumab
03/25/2011